The primary purpose of Корвалол-МФФ (Corvalol-MFF) is to offer supportive symptomatic relief in situations where symptoms related to heightened physiological activity are present. The medication is considered relevant across three main therapeutic domains, as it contains Phenobarbital, a component applied for sedative purposes. The medication may be part of symptomatic management for conditions characterized by periods of heightened symptoms, including those associated with mild neuroses, nervous excitability, intestinal spasms, and sleep initiation difficulties caused by tension.

“The medication provides supportive relief when symptoms interfere with routine activities.”

It helps address symptom clusters like general inner distress and irritability, providing support that contributes to easing the overall symptom burden. The medication is commonly used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable, and may assist with easing symptoms linked to stress, such as functional palpitations.

---

Quick Fact: Supportive Management for Tension

Symptom Domain	Key Benefit	Clinical Context
Symptoms related to Nervous Irritability	Supports comfort during symptomatic periods	Used during phases of increased emotional distress
Symptoms related to Functional Spasms	Assists with physical comfort	Applied in scenarios where additional management of discomfort is required
Symptoms related to Sleep Disruption	Contributes to easing distress before rest	Relevant when symptoms interfere with daily comfort

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Корвалол-МФФ?

Eligibility for Корвалол-МФФ is defined by official regulatory documents, strictly classifying populations who may use the medicine and those who are formally prohibited. Use is generally established for non-contraindicated adults (18 years and older).

---

Absolute Contraindications (Must Not Use)

Official labeling mandates that the medicine must not be used by individuals under 18 years of age or by women during pregnancy and lactation. Absolute contraindications also apply to patients with severe hepatic insufficiency (liver failure) or severe renal insufficiency (kidney failure).

Additional contraindications include a documented hypersensitivity to any component, Porphyria, acute myocardial infarction, arterial hypotension, and severe respiratory conditions such as severe COPD or asthma.

---

Restricted and Conditional Use

Caution is required when the medicine is used in older adult patients (geriatric population), and in individuals with mild to moderate hepatic or renal impairment.

The oral solution form is specifically contraindicated in populations with conditions sensitive to alcohol, including alcoholism, diabetes mellitus, and traumatic brain injury, due to its ethanol content.

Interactions with other medicines and products

Interactions with this product are predominantly driven by its component, phenobarbital, which is a potent inducer of hepatic enzymes (e.g., CYP450 system). This enzyme induction accelerates the breakdown and reduces the concentration of many co-administered medicines, diminishing their therapeutic effectiveness.

Pharmacokinetic Interactions (Altered Concentration)

This product may significantly reduce the plasma concentration and efficacy of medicines metabolized by induced enzymes. Concomitant use with the following classes or agents requires caution and monitoring:

• Anticoagulants (e.g., Warfarin): Risk of reduced effect, leading to potential treatment failure.
• Hormonal Contraceptives (e.g., Oral Contraceptives): Efficacy is reduced, requiring the use of alternative or additional non-hormonal birth control methods.
• Immunosuppressants (e.g., Cyclosporine): Risk of reduced concentration, which may lead to loss of therapeutic effect and possible graft rejection.
• Glucocorticoids and Antiepileptics (e.g., Phenytoin, Carbamazepine): Metabolism is accelerated, necessitating dose adjustment and close monitoring.

Pharmacodynamic Interactions (Altered Effect)

Concomitant use with other agents that cause Central Nervous System (CNS) depression results in an additive sedative effect. These combinations require extreme caution or should be avoided, including use with other sedatives, anxiolytics, and alcohol.

The physiological modulation achieved by Корвалол-МФФ results from the synergistic action of its two principal components: ethyl alpha-bromoisovalerate and phenobarbital. The primary site of action is the central nervous system, particularly the subcortical structures involved in autonomic regulation.

Ethyl alpha-bromoisovalerate is metabolized to isovaleric acid, which functions as a positive allosteric modulator of the GABA-A receptor complex. It binds to a distinct site on the receptor, increasing the frequency of the chloride ion channel openings. This facilitated influx of negatively charged chloride ions induces neuronal hyperpolarization, reducing the cell’s inherent excitability and dampening firing rates within the CNS.

Phenobarbital, a barbiturate derivative, also interacts with the GABA-A receptor but at a separate binding site. Its interaction prolongs the duration of chloride channel opening, further potentiating the inhibitory action of the neurotransmitter gamma-aminobutyric acid (GABA).

This combined central depressant effect culminates in the attenuation of excitability within the brain's vasomotor centers. The components also possess a localized, direct effect on peripheral smooth muscle cells, contributing to a reduction in intrinsic muscle tone within vascular and gastrointestinal tissues.

How to use Корвалол-МФФ — Official Administration Guidelines

This section outlines the instructions for the use of Корвалол-МФФ based strictly on official documentation.

---

Administration Scope

Feature	Official Instruction
Route of Administration	Oral
Timing in Relation to Meals	Before meals
Preparation Requirements	Not stated; administered as drops with liquid

---

Official Dosing and Frequency

User Group	Dosage (Single)	Frequency	Special Conditions
Adults (Usual Dose)	15 to 30 drops	2 to 3 times per day	To be taken with a small amount of liquid.
Adults (Max Dose)	40 to 50 drops	Single use only	For severe manifestations or insufficient response to the usual dose.
Children	Not recommended	Not applicable	Use in pediatric populations is not advised.

---

Procedural Rules

The administration sequence mandates the patient to measure the prescribed number of drops and combine them with a small volume of liquid. This dose must be taken orally prior to consuming a meal. The standard frequency is two to three times per day. The instructions do not specify a rule for managing a missed dose. The use of this drug is solely for adults, as official documents explicitly do not recommend its administration to children.

---

Connection to the Overall Use Protocol

The regulatory use protocol for Корвалол-МФФ is defined by a simple, fixed-frequency, oral administration schedule. The procedure involves a minimal preparation step of diluting the drops in liquid before ingestion, always specifying that this must occur before meals and up to three times daily. The dosing is explicitly age-gated, focusing entirely on adult use, with a pre-defined range for routine use and a documented exception for increasing the dose in cases of greater need.

Корвалол-МФФ: Recent Clinical Evidence

Clinical research on Corvalol (Корвалол-МФФ), a drug containing phenobarbital and ethyl alpha-bromoisovalerate, has focused primarily on its use as a sedative, antispasmodic, and vasodilator agent within the healthcare systems of Eastern Europe and the former Soviet Union.

Status of Efficacy Data

The efficacy of Corvalol's components for its traditional uses (such as treating neuroses, insomnia, non-acute coronary vessel spasms, and hypertension) remains debated in international scientific literature.

• Phenobarbital: This is a long-acting barbiturate and nonselective central nervous system (CNS) depressant. Its use in modern Western medicine is primarily restricted to treating epilepsy and status epilepticus. Currently, there is a lack of high-quality Randomized Controlled Trials (RCTs) to support its benefit in treating cardiovascular or respiratory conditions.
• Ethyl Alpha-Bromoisovalerate: This component, derived from valerian, is traditionally associated with mild sedative and spasmolytic effects. Evidence supporting its efficacy, or that of valerian-based compounds, for conditions like anxiety and insomnia is often described as limited or inconclusive in formal meta-analyses.

---

Safety and Pharmacological Considerations

The most significant clinical focus involves the phenobarbital content, which has a long half-life and carries risks related to CNS depression, respiratory depression, and dependency upon prolonged use. Phenobarbital is known to interact with the GABA-A receptor, thereby increasing synaptic inhibition.

Due to the inclusion of phenobarbital, Corvalol is regulated in many countries (such as the United States) as a controlled substance and is illegal to import. Patients and healthcare providers are advised to consider that phenobarbital is a strong inducer of hepatic cytochrome P450 enzymes (e.g., CYP3A4), which can potentially reduce the effectiveness of many other prescription medications taken concurrently.

Common questions about Корвалол-МФФ (FAQ)

Q: Can Корвалол-МФФ affect a person's ability to safely drive or operate machinery?

Regulatory information for medicines with central nervous system (CNS) depressant effects, like the components in Корвалол-МФФ, often includes functional warnings. Because this medicine can cause sedation and affect concentration, label information indicates that it may impair a person's ability to safely drive or operate machinery.

Q: Are there any specific types of food or drinks that should be avoided when taking Корвалол-МФФ?

Official instructions state the drops should be taken before meals. The absorption of the component Phenobarbital is known to be faster when taken on an empty stomach. Beyond the explicit regulatory warning to avoid alcohol, official documents do not list specific food interactions.

Q: What does the latest research evidence indicate about the main components of Корвалол-МФФ?

Official regulatory analyses indicate that clinical research on the efficacy of Corvalol for some of its traditional uses remains limited or inconclusive in formal meta-analyses. The primary safety focus involves the component Phenobarbital, which is a recognized CNS depressant associated with risks of dependence and other safety concerns.

Q: Has Корвалол-МФФ been evaluated or approved by Western bodies like the FDA or EMA?

Official governmental sources confirm that Corvalol is not approved by the U.S. Food and Drug Administration (FDA) for domestic distribution. Due to the inclusion of Phenobarbital, it is classified as a controlled substance in the U.S. and is generally restricted from importation for personal use.

Q: What should a patient generally expect to feel after the medicine starts working?

According to the official product information, the drug is intended to provide a calming effect and general tension relief. This result is linked to its sedative properties. The intended effects are described as reduced excitability, which may be accompanied by documented common effects such as sedation or drowsiness.

Q: Does tolerance build up if Корвалол-МФФ is used regularly for a period of time?

Official warnings emphasize the risk of physical and psychological dependence with long-term use of this medicine. Dependence is closely related to the concept of tolerance, which describes a state where the body may require increasingly larger doses to achieve the initial therapeutic effect.

Q: How does Корвалол-МФФ compare to other similar drops like Валокордин?

Historical and compositional information shows that Corvalol was developed as an analogue of the German product Valocordin. Due to this relationship, the two products are recognized as having a similar composition, with both primarily containing the component phenobarbital and a valerian derivative.

Q: How long does it typically take for the effects of Корвалол-МФФ to begin after taking it?

Official pharmacokinetic information, which tracks how the body handles the drug, indicates that the oral absorption of the component Phenobarbital is characteristically slow. This means the concentration of the drug reaches its maximum level in the bloodstream typically several hours after a single dose.

Q: What is the usual duration of action for the drops?

The component Phenobarbital is classified as a long-acting barbiturate. Its prolonged effect is reflected in its long plasma half-life—the time needed for the body to reduce the amount in the blood by half. For adults, this half-life is described in official data as extending up to 100 hours.

Q: Does Корвалол-МФФ interact with common pain relievers or NSAIDs?

Regulatory interaction warnings state that the Phenobarbital component is a potent inducer of certain liver enzymes. This induction can significantly accelerate the breakdown of many co-administered medicines, potentially reducing their effectiveness.

Q: Is the quantity of drops taken influenced by body weight according to the instructions?

The standard regulatory dose for adults is a fixed range of drops, independent of body weight. However, it is noted that the clinical dosing for the component Phenobarbital in related medical practice is often calculated based on body weight (mg per kg), which indicates weight is a factor in some guidelines.

Q: Is it described as a remedy for 'cardioneurosis' in official literature?

The official product label indicates the drug for general 'neuroses with heightened irritability' and certain non-acute spasms. The specific term 'cardioneurosis' is not consistently present as a primary standalone indication in the main regulatory documents for this drug.

Q: What does the official document say about signs of taking too much of the medicine?

Official warnings for the Barbiturate class describe signs of toxicity (overdose) as ranging from severe sedation and confusion. More dangerous signs include respiratory depression (shallow or slow breathing), very low blood pressure (profound hypotension), and coma.

The official storage and disposal profile for Корвалол-МФФ is defined by its governing national regulatory body to maintain the stability of its multi-component formulation, which includes an alcohol-based solution.

Storage & Disposal Scope

Scope Category	Official Regulatory Requirements
Labeled storage temperature requirements	Store at a temperature not exceeding 25 C (77 F).
Light/moisture protection requirements	The product must be protected from light. Keep in the original container.
Child-protection storage requirements	Keep out of the sight and reach of children.
Handling requirements	The container must be kept tightly closed to prevent the evaporation of volatile components.
Disposal instructions	Unused or expired medication must be disposed of according to local regulatory requirements for pharmaceutical waste.

These constraints are critical for preserving the potency of the active ingredients, particularly the Phenobarbital and the volatile Peppermint Oil component.